Literature DB >> 16887799

Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity.

Mariano Ubeda1, J Michael Rukstalis, Joel F Habener.   

Abstract

Type 2 diabetes (T2D) and Alzheimer disease are degenerative diseases that may share common pathophysiologic mechanisms. Neuronal dysfunction in Alzheimer patients has been linked to overactivity of the cyclin-dependent kinase 5 (CDK5) and its activator p35. Both of these proteins are expressed in the insulin-producing beta cells of the pancreas. Further, glucose enhances p35 gene expression, promoting the formation of active p35/CDK5 complexes that regulate the expression of the insulin gene. In T2D, chronic elevations of glucose, glucotoxicity, impair beta cell function. We therefore postulated that CDK5 and p35 may be responsible for this beta cell impairment and that inhibition of CDK5 might have a beneficial effect. To test this hypothesis, the pancreatic cell line INS-1 was selected as a known in vitro model of glucotoxicity, and roscovitine (10 mum) was used as a CDK5 inhibitor. Chronic exposure of INS-1 cells to high glucose (20-30 mm) reduced both insulin mRNA levels and the activity of an insulin promoter reporter gene. Inhibition of CDK5 prevented this decrease of insulin gene expression. We used DNA binding (gel shift) assays and Western immunoblots to demonstrate that cellular levels of the transcription factor PDX-1, normally decreased by glucotoxicity, were preserved with CDK5 inhibition, as was the binding of PDX-1 to the insulin promoter. Analyses of nuclear and cytoplasmic PDX-1 protein levels revealed that CDK5 inhibition restores nuclear PDX-1, without affecting its cytoplasmic concentration, suggesting that CDK5 regulates the nuclear/cytoplasm partitioning of PDX-1. Using a Myc-tagged PDX-1 construct, we showed that the translocation of PDX-1 from the nucleus to the cytoplasm during glucotoxic conditions was prevented when CDK5 was inhibited. These studies indicate that CDK5 plays a role in the loss of beta cell function under glucotoxic conditions and that CDK5 inhibitors could have therapeutic value for T2D.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887799     DOI: 10.1074/jbc.M604690200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Association of rs7754840 G/C polymorphisms in CDKAL1 with type 2 diabetes: a meta-analysis of 70141 subjects.

Authors:  Muhadasi Tuerxunyiming; Patamu Mohemaiti; Hamulati Wufuer; Awaguli Tuheti
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  The association analysis polymorphism of CDKAL1 and diabetic retinopathy in Chinese Han population.

Authors:  Nai-Jia Liu; Qian Xiong; Hui-Hui Wu; Yan-Liang Li; Zhen Yang; Xiao-Ming Tao; Yan-Ping Du; Bin Lu; Ren-Ming Hu; Xuan-Chun Wang; Jie Wen
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

3.  Replication study of novel risk variants in six genes with type 2 diabetes and related quantitative traits in the Han Chinese lean individuals.

Authors:  Xiao Yun Bao; Bin Peng; Mao Sheng Yang
Journal:  Mol Biol Rep       Date:  2011-06-05       Impact factor: 2.316

4.  A genomics study of type 2 diabetes mellitus in U.S. Air Force personnel.

Authors:  Lisa Lott
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

5.  Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.

Authors:  John P Eggers; Paul M Grandgenett; Eric C Collisson; Michelle E Lewallen; Jarrod Tremayne; Pankaj K Singh; Benjamin J Swanson; Judy M Andersen; Thomas C Caffrey; Robin R High; Michel Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2011-08-08       Impact factor: 12.531

Review 6.  Translational implications of the β-cell epigenome in diabetes mellitus.

Authors:  Justin S Johnson; Carmella Evans-Molina
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

7.  PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.

Authors:  Tatsuyoshi Kono; Geonyoung Ahn; Dan R Moss; Liann Gann; Angel Zarain-Herzberg; Yurika Nishiki; Patrick T Fueger; Takeshi Ogihara; Carmella Evans-Molina
Journal:  Mol Endocrinol       Date:  2012-01-12

8.  Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population.

Authors:  Yong-Ho Lee; Eun Seok Kang; So Hun Kim; Seung Jin Han; Chul Hoon Kim; Hyeong Jin Kim; Chul Woo Ahn; Bong Soo Cha; Moonsuk Nam; Chung Mo Nam; Hyun Chul Lee
Journal:  J Hum Genet       Date:  2008-11-11       Impact factor: 3.172

9.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 10.  The emerging genetic architecture of type 2 diabetes.

Authors:  Alessandro Doria; Mary-Elizabeth Patti; C Ronald Kahn
Journal:  Cell Metab       Date:  2008-09       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.